Low NLRP3 expression predicts a better prognosis of colorectal cancer

Feng Shi, Bo Wei, Tian Lan, Yang Xiao, Xin Quan, Jun Chen, Chong Zhao, Jinhang GaoBioscience 2021 · DOI

TL;DR

This study reveals that higher expression of NLRP3, an inflammasome component, is associated with poorer survival in colorectal cancer (CRC) patients. This finding positions NLRP3 as a potential prognostic biomarker and therapeutic target for CRC.

What Problem Does This Paper Address?

Colorectal cancer (CRC) remains a significant health challenge, with prognosis heavily influenced by the stage at diagnosis. Despite advancements, identifying reliable risk factors for CRC progression and prognosis is crucial for improving patient outcomes. Inflammasomes, particularly the NLRP3 inflammasome, are known to play a complex role in inflammation and tumorigenesis, but their specific impact on CRC prognosis was unclear. This paper aims to elucidate the relationship between NLRP3 expression levels and the prognosis of CRC.

Methods

The researchers employed a multi-pronged approach:

  • Immunohistochemistry (IHC): This standard technique was used to quantify NLRP3 expression in human colorectal adenocarcinoma tissue microarrays (TMAs) and in xenograft mouse models.
  • Western Blotting: Used to measure NLRP3 protein levels in both human tissues and xenografts, complementing the IHC findings.
  • Quantitative Real-Time PCR (qRT-PCR): Employed to assess the mRNA levels of inflammatory cytokines IL1β and IL18.
  • Cell Culture Assays: HCT116 and RKO colon cancer cell lines were used for in vitro experiments.
  • Cell Counting Kit-8 (CCK8) Assay: To evaluate cell viability and the effect of an NLRP3 inhibitor.
  • Flow Cytometry: To analyze cell cycle progression and apoptosis.
  • Xenograft Models: Human CRC cells (HCT116 and RKO) were implanted into nude mice to create in vivo models for studying tumor growth and NLRP3 expression.
  • Statistical Analysis: Kaplan-Meier survival analysis and multivariable Cox proportional hazards regression were used to assess the correlation between NLRP3 expression and patient survival, and to identify independent risk factors.

Datasets

The study utilized two primary datasets:

  1. Human Colorectal Cancer Tissue Microarrays (TMAs): Comprising 100 colon adenocarcinoma cases and 60 corresponding paracancerous tissues. This dataset was used for IHC analysis and clinicopathological correlation.
  2. Human CRC Xenografts: Established by injecting HCT116 or RKO cells into nude mice. These models were used to validate findings from human tissues and for mechanistic studies.

Key Insights and Ideas

  • NLRP3 as a Double-Edged Sword: The paper acknowledges the complex, context-dependent role of NLRP3 in cancer, highlighting that while it can be protective in some inflammatory contexts, it appears to promote CRC progression in others.
  • NLRP3's Role in Tumor Microenvironment: The findings suggest that increased NLRP3 expression might negatively impact the anti-tumor immune response, potentially by promoting the accumulation of myeloid-derived suppressor cells (MDSCs) or impairing NK cell function.
  • Inflammation-Driven Progression: The study posits that excessive colorectal inflammation, potentially mediated by NLRP3 and its downstream cytokines (IL1β and IL18), drives CRC progression and metastasis.
  • Therapeutic Potential: The successful inhibition of cancer cell proliferation and induction of apoptosis by the NLRP3 inhibitor MCC950 points towards NLRP3 as a viable therapeutic target.

Key Results

  • NLRP3 Upregulation in CRC: NLRP3 expression was significantly higher in colon adenocarcinoma tissues compared to adjacent paracancerous tissues, both at the mRNA and protein levels. This was consistent in both human TMAs and xenograft models.
  • Correlation with Advanced Disease: High NLRP3 expression was strongly correlated with advanced TNM stage, the presence of distant metastasis and vascular invasion, and positive lymph nodes.
  • Prognostic Significance: Kaplan-Meier survival analysis revealed that patients with high NLRP3 expression had significantly poorer 5-year and 10-year overall survival rates compared to those with low NLRP3 expression.
  • Independent Risk Factor: Multivariable Cox proportional hazards regression identified high NLRP3 expression as an independent risk factor for poor prognosis in CRC patients, alongside age, metastasis, and positive lymph nodes.
  • Mechanistic Insights: Inhibition of NLRP3 using MCC950 suppressed HCT116 cell proliferation, induced apoptosis, and reduced the mRNA levels of IL1β and IL18.

Limitations and Future Work

  • Controversial Role of NLRP3: The authors acknowledge that the role of NLRP3 in cancer is debated, with some studies suggesting it acts as a tumor suppressor. Further research is needed to fully elucidate its complex mechanisms.
  • Molecular Mechanism: While the study demonstrates that MCC950 affects cell proliferation and apoptosis via IL1β and IL18, the precise molecular and cellular mechanisms by which increased NLRP3 promotes CRC progression and metastasis require further investigation.
  • Immunocyte Involvement: The hypothesis that immune micromovement contributes to poor prognosis in high NLRP3 CRC patients is supported by evidence, but more direct experimental validation of NLRP3's impact on specific immune cell populations in vivo would strengthen this conclusion.
  • Clinical Translation: While NLRP3 shows promise as a prognostic biomarker and therapeutic target, further validation in larger, diverse patient cohorts and preclinical studies are necessary before clinical application.

Summary updated

Abstract

High level of NLRP3 predicts poor survival in CRC patients. NLRP3 is a putative prognostic biomarker and a potential therapeutic target in CRC treatments.
BibTeX
@inproceedings{shi2021low,
  author = {Feng Shi and Bo Wei and Tian Lan and Yang Xiao and Xin Quan and Jun Chen and Chong Zhao and Jinhang Gao},
  title = {{Low NLRP3 expression predicts a better prognosis of colorectal cancer}},
  booktitle = {Bioscience},
  year = {2021},
  doi = {10.1042/bsr20210280},
}
Figure